Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (24)	8/7/2009 10:14:27 PM
From: John McCarthy	1 Recommendation Respond to of 421

TD I don't follow it anymore.

To: Arthur Radley who wrote (24)	8/11/2009 12:18:12 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 421

Journal of Ocular Pharmacology and Therapeutics Fluocinolone Inhibits VEGF Expression via Glucocorticoid Receptor in Human Retinal Pigment Epithelial (ARPE-19) Cells and TNF-a–Induced Angiogenesis in Chick Chorioallantoic Membrane (CAM) -------------------------------------------------------------------------------- To cite this article: Surya P. Ayalasomayajula, Paul Ashton, Uday B. Kompella. Journal of Ocular Pharmacology and Therapeutics. April 2009, 25(2): 97-104. doi:10.1089/jop.2008.0090. -------------------------------------------------------------------------------- Published in Volume: 25 Issue 2: April 8, 2009 Online Ahead of Print: March 14, 2009 -------------------------------------------------------------------------------- Full Text: • PDF for printing (270 KB) • PDF w/ links (239.2 KB) Surya P. Ayalasomayajula University of Nebraska Medical Center, Omaha, Nebraska. DMPK-ClinPKPD, Novartis Pharmaceuticals Co., East Hanover, New Jersey. Paul Ashton pSivida Inc., Watertown, Massachusetts. Uday B. Kompella University of Nebraska Medical Center, Omaha, Nebraska. University of Colorado Denver, Department of Pharmaceutical Sciences, Aurora, Colorado. Purpose: The purpose of this study was to determine whether fluocinolone inhibits vascular endothelial growth factor (VEGF) expression in a retinal pigment epithelial cell line (ARPE-19) and TNF-a–induced angiogenesis in chick chorioallantoic membrane (CAM) assay. Methods: The dose-dependent effect of fluocinolone (0.0001–1 µM) on VEGF secretion, VEGF mRNA expression, and cytotoxicity was determined in confluent monolayers of ARPE-19 cells using ELISA, RT-PCR, and MTT assay, respectively. The effect of a glucocorticoid receptor antagonist (RU486) on fluocinolone-mediated VEGF expression was determined. The effect of fluocinolone in inhibiting TNF-a–induced angiogenesis was determined using chick chorioallantoic membrane (CAM) assay. The dose-dependent effect of fluocinolone (0.0001–1 µM) in inhibiting 1% serum-stimulated ARPE-19 cell proliferation was determined using BrdU labeling assay. Results: At concentrations devoid of cytotoxicity, fluocinolone inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells. RU486 (1 µM) treatment prevented inhibition of VEGF secretion and VEGF mRNA expression by fluocinolone (0.1 µM). Fluocinolone (50 ng/egg) inhibited angiogenesis induced by TNF-a. The ARPE-19 cell proliferation was inhibited by fluocinolone in a dose-dependent manner. Conclusions: Fluocinolone inhibited VEGF expression in ARPE-19 cells via its glucocorticoid receptor activity. In addition, fluocinolone inhibited proliferation of ARPE-19 cells and TNF-a–induced angiogenesis in chorioallantoic membranes.